Our proprietary bacterial exosome platform overcomes critical manufacturing barriers to unlock the potential of exosomes to deliver safe and cost-effective treatment for inflammatory GI diseases.
Traditional exosome therapeutics face limited scalability, high costs, and require IV administration. BEX™ transforms these hurdles into advantages: genetically engineered probiotic bacteria produce orally bioavailable exosomes at 60-fold higher yields, 3-fold greater potency, while maintaining exceptional quality.
